Trials / Completed
CompletedNCT00533676
Endpoint Validation Study (0524A-015)
A Randomized, Double-Blind, Placebo-Controlled Endpoint Selection and Questionnaire Validation Study to Assess the Niacin Induced Flushing Caused by NIASPAN (TM)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (planned)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0524A, /Duration of Treatment : 8 Weeks | |
| DRUG | Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2007-09-21
- Last updated
- 2017-02-17
Source: ClinicalTrials.gov record NCT00533676. Inclusion in this directory is not an endorsement.